Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Profound Medical Corp T.PRN

Alternate Symbol(s):  PROF

Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.


TSX:PRN - Post by User

Comment by BuenaSuertaAtodon Oct 17, 2021 11:46am
212 Views
Post# 34015032

RE:RE:RE:Research Capital: Take a pass on Profound Medical

RE:RE:RE:Research Capital: Take a pass on Profound MedicalMrMugsy,

I'm thinking that their plans for 25 installations by 2022 & 7 or 8 additional sites per quarter then (with doubled sales & installation teams) and then up to 10 installations per quarter, with treatments per site per year ramping up to 100, should make us ``look exciting sooner (rather than later)`` as you say. 

I think the revenue & profit snowball effect from all those new sites being added, together with increasing treatment activity per site, and maybe some increases in the `price point of $7710 or more` per treatment could make PRN a large takeover target in less than 5 years. Any thoughts as to who the suitors might be, or how open PRN is to being bought? 




MrMugsy wrote: What are we losing right now?  $7-8M per quarter?

As we ramp up we're going to have one-time costs to get new locations set-up along with paying for the equipment at those locations.  I think PRN is also working on ramping up sales staff to accomodate future growth.

Let's double our present losses for the next frew years for the above mentioned ramping up
1.  TULSA sales
2.  bringing Sonalleve to the USA
3.  costs for ongoing work/studies (both Sonalleve and TULSA) including clinical work in Germany
4.  upgrades to our hardware/software.
5.  not sure if they are working on developing a 2-in-1 TULSA/Sonalleve yet but I'd bet on that.

Ramping up to $16M per quarter ... we're potentially looking at $64M at peak losses.

By then we're likely developing flexible end-tools to deal with colon cancer - or - paying for further Sonalleve development for outside/in cancer treatments.

Are we also ramping up in other geographies by then - beyond the USA?

I have no clue what the strategy will look like but there are many ways for them to spend the money if they really want to.  Then again, there are ways to reduce costs if they really wanted to.  I'm betting on rapid growth to make us look exciting sooner (rather than later) and make us a takeover target within the next 5-10 years.

IMO only.





HomerAndCompany wrote:


I took another look at Andre Uddin's analysis and I found this part surprising:

Uddin projects "revenues of $16.1 million in 2021, then more than doubling to a projected $33.8 million for 2022, $47.9 million for 2023, $63.8 million in 2024, then climbing to $71.4 million for 2025, which is also the first year Uddin forecasts positive values for earnings per share and cash flow per share"

He sees exponential revenue growth for 2021 and 2022 with respectable growth thereafter (though despite "Uddin noting that the (CPT-1) code becoming effective in January 2024 would significantly accelerate TULSA-PRO’s sales growth." he doesn't show anything like exponential growth resulting). Profound's projections for new installations should mean exponential growth through 2021 & 2022 if not beyond.

What surprises me is that Uddin sees negative earnings even as revenue climbs over $60 million in his 2024 projection. I'd expect that a growing percentage of the revenue increases would be high margin recurring revenue with much of it going to the bottom line.
For example the $2.6 million revenue in Q2 corresponds to $10.4 million revenue annualized with a $28.560 million annualized loss. All other things being equal, if you add $50 million in very high margin revenue you might expect to cover that $28.560 deficit and then some. Of course all other things are never quite equal - doubling sales and installation teams will increase expenses.
Does anyone have a better understanding of Uddin's forecast? Does anyone out there know how PRN would gernerate a loss with over $60 million in revenue?  
-TIA! 
 




<< Previous
Bullboard Posts
Next >>